Current Urology Reports

, Volume 5, Issue 6, pp 472–477 | Cite as

Testosterone treatment for the aging man: The controversy

  • Alvaro Morales


The issues surrounding androgen replacement therapy in men with symptomatic late-onset hypogonadism has been marred in controversy even before the identification and synthesis of testosterone. The controversy has attained renewed importance because of the ever increasing aging population. Physicians attuned with the various diagnostic approaches, familiar with the advantages and drawbacks of testosterone preparations, and aware of the potential safety issues are well positioned to deal with the hypogonadal man at or beyond middle age. The urologist is in a unique position to assist patients and colleagues in other specialties, particularly in relation to prostate safety. This update focuses on the most prominent areas of controversy.

References and Recommended Reading

  1. 1.
    Wagner AA: The male climacteric: report of two hundred and seventy three cases. JAMA 1946, 132:188–194.Google Scholar
  2. 2.
    Writing Group for the Women’s Health Initiative: Risks and benefits of estrogens and progestins in healthy post-menopausal women. JAMA 2002, 288:321–327.CrossRefGoogle Scholar
  3. 3.
    Muller M, van der Schouw YT, Thijssen JH, et al.: Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003, 88:5076–5086. This extensive review provides evidence that sex hormones do not have negative cardiovascular effects in men.PubMedCrossRefGoogle Scholar
  4. 4.
    Liverman CT, Blazer DG: Testosterone and Aging. Committee on Assessing the Need for Clinical Trials of Testosterone Replacement Therapy. Washington D.C.: Institute of Medicine of the National Academies, The National Academies Press; 2004. The IOM report gives a comprehensive view of the current understanding about the effects of T supplementation. It calls for further research and strict indications for the use of androgen supplementation.Google Scholar
  5. 5.
    Vermeulen A, Verdonck L, Kaufman JL: A critical evaluation of simple method for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999, 84:3666–3672.PubMedCrossRefGoogle Scholar
  6. 6.
    Morley JE, Ping P, Perry HM III: Evaluations of assays available to measure free testosterone. Metabolism 2002, 51:554–559.PubMedCrossRefGoogle Scholar
  7. 7.
    Hak AE, Witteman JC, de Jong FH, et al.: Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: The Rotterdam Study. J Clin Endocrinol Metab 2002, 87:3632–3639.PubMedCrossRefGoogle Scholar
  8. 8.
    Malkin CJ, Pugh PJ, Jones RD, et al.: The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab 2004, 87:3313–3318.CrossRefGoogle Scholar
  9. 9.
    Litvinov IV, De Marzo AM, Isaacs JT: Is the Achilles’ heel for prostate cancer therapy a gain of function in androgen receptor signaling? J Clin Endocrinol Metab 2003, 88:2972–2982.PubMedCrossRefGoogle Scholar
  10. 10.
    Nelson WG, De Marzo AM, Issacs WB: Mechanisms of disease: prostate cancer. N Engl J Med 2003, 349:366–361. Anyone interested in the mechanisms of prostate cancer development and the role of the androgen receptor would enjoy this review.PubMedCrossRefGoogle Scholar
  11. 11.
    Morales A: Androgen replacement therapy and prostate safety. Eur Urol 2002, 26:113–120.CrossRefGoogle Scholar
  12. 12.
    Marcelli M, Cunningham GR: Hormonal signaling in prostatic hyperplasia and neoplasia. J Clin Endocrinol Metab 1999, 84:3463–3468.PubMedCrossRefGoogle Scholar
  13. 13.
    Gann PH, Hennekens CH, Longcope C, et al.: A prospective study of hormone plasma levels, non-hormonal factors, and development of benign prostatic hyperplasia. Prostate 1995, 26:40–49.PubMedCrossRefGoogle Scholar
  14. 14.
    Wang C, Swerdloff RS. Editorial: Should the non-aromatizable androgen dehydrotestosterone be considered as an alternative to testosterone in the treatment of the andropause? J Clin Endocrinol Metab 2002, 87:1462–1466.PubMedCrossRefGoogle Scholar
  15. 15.
    Carson C III, Rittmaster R: The role of dehydrotestosterone in benign prostatic hyperplasia. Urology 2003, 61(suppl. 4A):2–7.PubMedCrossRefGoogle Scholar
  16. 16.
    Behre HM: Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol (Oxf) 1994, 40:341–349.Google Scholar
  17. 17.
    Meikle AW, Arver S, Dobbs AS, et al.: Prostate size in hypogonadal men treated with a nonscrotal permeation enhanced testosterone transdermal system. Urology 1997;49:191–196.PubMedCrossRefGoogle Scholar
  18. 18.
    Tenover JL: Androgen deficiency in aging men. Aging Male 1998, Supplement 1:16–21.Google Scholar
  19. 19.
    Wright EJ, Fang J, Metter EJ, et al.: Prostate-specific antigen predicts the long-term risk of prostate enlargement: results of the Baltimore Longitudinal Study of Aging. J Urol 2002, 167:2484–2488.PubMedCrossRefGoogle Scholar
  20. 20.
    Wang C, Swerdloff RS, Iranmanesh A, et al.: Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J Clin Endocrinol Metab 2000, 85:2839–2853.PubMedCrossRefGoogle Scholar
  21. 21.
    Swerdloff RS, Wang C: Three-year follow-up of androgen treatment in hypogonadal men: preliminary report with testosterone gel. Aging Male 2003, 6:207–211.PubMedGoogle Scholar
  22. 22.
    McNicholas TA, Dean JD, Mulder H, et al.: A novel testosterone gel formulation normalizes androgen levels in hypogonadal men, with improvements in body composition and sexual function. BJU Int 2003, 91:69–74.PubMedCrossRefGoogle Scholar
  23. 23.
    Carson C III, Rittmaster R: The role of dehydrotestosterone in benign prostatic hyperplasia. Urology 2003, 61(suppl 4A):2–7.PubMedCrossRefGoogle Scholar
  24. 24.
    Behre HM: Prostate volume in treated and untreated hypogonadal men in comparison to age-matched controls. Clin Endocrinol (Oxf) 1994, 40:341–349.Google Scholar
  25. 25.
    Eaton NE, Reeves GK, Appleby PN, et al.: Endogenous sex hormones and prostate cancer: a quantitative review of prospective studies. Br J Cancer 1999, 80:930–934.PubMedCrossRefGoogle Scholar
  26. 26.
    Shaneyfelt T, Husein R, Bubley G, et al.: Hormonal predictors of prostate cancer: a meta-analysis. J Clin Oncol 2000, 18:847–853.PubMedGoogle Scholar
  27. 27.
    Slater S, Oliver RT: Testosterone: its role in the development of prostate cancer and potential risks for use as hormone replacement therapy. Drugs Aging 2000, 17:431–439.PubMedCrossRefGoogle Scholar
  28. 28.
    Mohr BA, Feldman HA, Kalish LA, et al.: Are serum hormones associated with the risk of prostate cancer? Prospective results from the Massachusetts Male Aging Study. Urology 2001, 57:930.PubMedCrossRefGoogle Scholar
  29. 29.
    Parsons JK, Carter HB, Landis P, et al.: Higher serum-free testosterone is associated with an increased risk of prostate cancer: results from the Baltimore Longitudinal Study on Aging [Abstract 439]. J Urol 2004, 171:116.CrossRefGoogle Scholar
  30. 30.
    Curran MJ, Bihrle W 3rd: Dramatic rise in PSA after androgen replacement in a hypogonadal man with occult adenocarcinoma of the prostate. Urology 1999, 53:423–424.PubMedCrossRefGoogle Scholar
  31. 31.
    Rhoden EL, Morgentaler A: Testosterone replacement therapy in hypogonadal men at risk for prostate cancer: results of 1 year of treatment in men with prostatic intraepithelial neoplasia. J Urol 2003, 170:2348–2351.PubMedCrossRefGoogle Scholar
  32. 32.
    Morales A, Buvat J, Gooren LJ, et al.: Endocrine aspects of male sexual dysfunction. J Sex Med 2004, 1:69–81.PubMedCrossRefGoogle Scholar
  33. 33.
    Kaufman JM, Graydon RJ: Androgen administration in hypogonadal men after radical prostatectomy for their prostate cancer [Abstract 1412]. J Urol 2004, 169:378.Google Scholar

Copyright information

© Current Science Inc 2004

Authors and Affiliations

  • Alvaro Morales
    • 1
  1. 1.Queen’s University and Centre for Advanced Urological ResearchKingstonCanada

Personalised recommendations